{
    "id": 5574,
    "fullName": "ERBB3 Q809R",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ERBB3 (HER3) Q809R lies within the protein kinase domain of the Erbb3 (Her3) protein (UniProt.org). Q809R confers a gain of Erbb3 (Her3) protein function, resulting in phosphorylation of Akt and Erk, as well as oncogenic transformation of Erbb2 (Her2) expressing cells (PMID: 23680147).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2065,
        "geneSymbol": "ERBB3",
        "terms": [
            "ERBB3",
            "c-erbB-3",
            "c-erbB3",
            "ErbB-3",
            "erbB3-S",
            "FERLK",
            "HER3",
            "LCCS2",
            "MDA-BF-1",
            "p180-ErbB3",
            "p45-sErbB3",
            "p85-sErbB3"
        ]
    },
    "variant": "Q809R",
    "createDate": "04/30/2015",
    "updateDate": "04/30/2015",
    "referenceTranscriptCoordinates": {
        "id": 123500,
        "transcript": "NM_001982",
        "gDna": "chr12:g.56097196A>G",
        "cDna": "c.2426A>G",
        "protein": "p.Q809R",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2124,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEHD7945A inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) Q809R (PMID: 23680147).",
            "molecularProfile": {
                "id": 5405,
                "profileName": "ERBB3 Q809R"
            },
            "therapy": {
                "id": 806,
                "therapyName": "Duligotuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2133,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell lines expressing ERBB3 (HER3) Q809R demonstrated resistance to treatment with Erbitux (cetuximab) (PMID: 23680147).",
            "molecularProfile": {
                "id": 5405,
                "profileName": "ERBB3 Q809R"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2163,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell lines expressing ERBB3 (HER3) Q809R in culture demonstrated a decreased response to Pictlisib (GDC-0941), showing inhibition of proliferation and colony formation, but to a lesser degree than other therapies (PMID: 23680147).",
            "molecularProfile": {
                "id": 5405,
                "profileName": "ERBB3 Q809R"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2127,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Herceptin (trastuzumab) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) Q809R (PMID: 23680147).",
            "molecularProfile": {
                "id": 5405,
                "profileName": "ERBB3 Q809R"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2119,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) Q809R (PMID: 23680147).",
            "molecularProfile": {
                "id": 5405,
                "profileName": "ERBB3 Q809R"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2130,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cell lines expressing ERBB3 (HER3) Q809R in culture demonstrated a decreased response to Perjeta (pertuzumab), showing inhibition of proliferation and colony formation, but to a lesser degree than other therapies (PMID: 23680147).",
            "molecularProfile": {
                "id": 5405,
                "profileName": "ERBB3 Q809R"
            },
            "therapy": {
                "id": 856,
                "therapyName": "Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2166,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of GDC-0941 and PD-0325901 (PI3K and MEK inhibitors, respectively) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) Q809R (PMID: 23680147).",
            "molecularProfile": {
                "id": 5405,
                "profileName": "ERBB3 Q809R"
            },
            "therapy": {
                "id": 1822,
                "therapyName": "PD-0325901 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 323,
                    "pubMedId": 23680147,
                    "title": "Oncogenic ERBB3 mutations in human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23680147"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 5405,
            "profileName": "ERBB3 Q809R",
            "profileTreatmentApproaches": [
                {
                    "id": 14811,
                    "name": "HER2 Inhibitor",
                    "profileName": "ERBB3 Q809R"
                },
                {
                    "id": 14814,
                    "name": "HER3 Inhibitor",
                    "profileName": "ERBB3 Q809R"
                },
                {
                    "id": 14810,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "ERBB3 Q809R"
                },
                {
                    "id": 14813,
                    "name": "Trastuzumab",
                    "profileName": "ERBB3 Q809R"
                },
                {
                    "id": 14812,
                    "name": "Pertuzumab",
                    "profileName": "ERBB3 Q809R"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 123500,
            "transcript": "NM_001982",
            "gDna": "chr12:g.56097196A>G",
            "cDna": "c.2426A>G",
            "protein": "p.Q809R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}